Compass Therapeutics, Inc. (CMPX)

Compass Therapeutics, Inc. stock has experienced significant activity and volatility over the past six months. The stock price increased by 230.30% from April 10, 2025, to April 9, 2026. Key events include earnings reports, clinical updates for tovecimig (CTX-009), participation in healthcare conferences, and analyst sentiment with a "Buy" or "Strong Buy" consensus. There have been reports of traders buying call options, and the stock experienced a downtrend according to the Aroon Indicator on certain dates.

As a clinical-stage biopharmaceutical company, Compass Therapeutics, Inc. does not currently have commercialized products or services that would exhibit traditional demand seasonality. Investor interest and clinical trial enrollment might experience fluctuations, but specific information on such seasonality was not found.

Compass Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on oncology, discovering and developing antibody-based therapeutics. Their pipeline includes CTX-009 (tovecimig), a bispecific antibody targeting DLL4 and VEGF-A, CTX-471, a CD137 agonistic antibody, CTX-8371, a PD-1 x PD-L1 bispecific antibody, and CTX-10726, a bispecific antibody targeting PD-1 and VEGF-A. The company is also exploring treatments for autoimmune diseases and utilizes platforms like StitchMabs™ for antibody engineering.

Compass Therapeutics, Inc. is headquartered in Boston, Massachusetts, and has an international reach through strategic partnerships. They have licensed global rights to CTX-009 (excluding South Korea) to ABL Bio, Inc., and China rights to Elpiscience Biopharmaceuticals Co., Limited.

Compass Therapeutics, Inc. generally holds a positive brand reputation among analysts and investors, driven by its strong pipeline and extended cash runway. The consensus analyst rating is "Strong Buy" or "Moderate Buy," with bullish sentiment from bloggers and news. Concerns include increased net loss due to R&D expenses and uncertainties in clinical trials. Despite challenges, the overall sentiment remains positive, with potential for growth and upside in stock performance.

Compass Therapeutics, Inc. has a significant institutional ownership presence, with 174 institutional owners and shareholders holding 163,381,290 shares. Major institutional owners include Tang Capital Management Llc, Orbimed Advisors Llc and Suvretta Capital Management, Llc. Carl L. Gordon is the largest individual shareholder, owning 15.22 million shares, representing 8.45% of the company.